A Resurrection of 7-MEOTA: A Comparison with Tacrine

Author(s): Ondrej Soukup, Daniel Jun, Jana Zdarova-Karasova, Jiri Patocka, Kamil Musilek, Jan Korabecny, Jan Krusek, Martina Kaniakova, Vendula Sepsova, Jana Mandikova, Frantisek Trejtnar, Miroslav Pohanka, Lucie Drtinova, Michal Pavlik, Gunnar Tobin, Kamil Kuca

Journal Name: Current Alzheimer Research

Volume 10 , Issue 8 , 2013

Become EABM
Become Reviewer
Call for Editor


Alzheimer´s disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from the market particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7- MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound – tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the tests related to a possible AD treatment. Only the pharmacokinetics and a higher acetylcholinesterase and butyrylcholinesterase inhibitory potency would slightly give advantages to tacrine over 7-MEOTA, but concerning its lower toxicity, better antioxidant properties, interaction with muscarinic and nicotinic receptors and “safer” metabolization provide strong evidence for reconsider 7-MEOTA and its derivatives as candidate molecules for the treatment of AD.

Keywords: 7-Methoxytacrine, Acetylcholinesterase inhibitor, Alzheimer´s disease drug, Cholinergic hypothesis, Pharmacological profile, Tacrine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 August, 2013
Page: [893 - 906]
Pages: 14
DOI: 10.2174/1567205011310080011
Price: $65

Article Metrics

PDF: 16